Oncology Medical News about Gemcitabine, oxaliplatin, biliary cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial
Cancer Chemotherapy and Pharmacology, 08/12/09

Jang JS et al. - In a study to evaluate the efficacy and safety of combination chemotherapy with gemcitabine and oxaliplatin (GEMOX) in pts with biliary tract cancers (BTCs) including gall bladder cancer, it was revealed that the GEMOX regimen demonstrated a modest antitumor activity and is well tolerated in pts with advanced BTCs.

Methods

A multicenter phase II study evaluated the efficacy and safety of GEMOX as first-line therapy in pts with advanced BTCs.
Eligible pts with previously untreated locally advanced or metastatic BTCs received gemcitabine 1000 mg/m2 (day 1 and 8) and oxaliplatin 100 mg/m2 (day 1), every 3 wks.

Results

53 pts were evaluated, 60% had cholangiocarcinoma and 40% gall bladder cancer; the objective response rate was 18.9% (10/53 pts including 1 Complete response) (14.9%) in the treated population.
Stable disease was observed in 27/53 (50.9%) pts, disease control rate was achieved in 69.8% of pts.
Median progression-free survival was 4.8 mos and median overall survival was 8.3 mos.
Grade 3/4 toxicities included neutropenia (33.9% of pts) and thrombocytopenia (7.6%).

<< Previous
A phase II study of sunitinib in patients with recurrent and/or...

Next >>
Rhythmic pattern of PCA opioid demand in adults with cancer pain